Skip to main content
. Author manuscript; available in PMC: 2021 Jul 22.
Published in final edited form as: Neuropharmacology. 2017 Sep 6;126:190–199. doi: 10.1016/j.neuropharm.2017.09.007

Figure 2.

Figure 2.

Effects of CAB2-015 or BAK4-54 on the maintenance of oxycodone (50 μg/kg/infusion) self-administration in rats. A: Systemic administration of CAB2-015 (0.4-10 mg/kg, i.p.; 15 min before session) dose-dependently decreased oxycodone self-administration as assessed by the total number oxycodone infusions (a), % change in oxycodone infusions (b), (or oxycodone intake (c).; B: Systemic administration of BAK4-54 (0.4-10 mg/kg, i.p.; 15 min before session) similarly inhibited oxycodone self-administration. *p<0.05, **p<0.01, compared to the vehicle pretreatment group. N=7-8/group.